DiBiase Mary
SEC CIK 1880179 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| XFOR | X4 Pharmaceuticals, Inc | COO | 1.14M | — | $144.1K | 23 | 2021-09-08 | 2025-02-12 |
Most active insiders at XFOR, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Craig Adam R | Executive COB, Dir | $250.0K | $210.8K |
| 2 | KIRSKE DAVID | CFO | — | $109.2K |
| 3 | Volpone John | Pres | — | $109.2K |
DiBiase Mary made no open-market trades at XFOR in the last 12 months.
Transactions 23
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-02-14 | 2025-02-12 | XFOR | X4 Pharmaceuticals, Inc | DiBiase Mary | COO | A - Grant | $0.00 | +650.0K | 1.14M | +132% | $0 | |
| 2025-01-27 | 2025-01-24 | XFOR | X4 Pharmaceuticals, Inc | DiBiase Mary | COO | S - Sale | $0.45 | -22.3K | 491.0K | -4% | -$10.0K | |
| 2025-01-27 | 2025-01-23 | XFOR | X4 Pharmaceuticals, Inc | DiBiase Mary | COO | A - Grant | $0.00 | +61.2K | 513.2K | +14% | $0 | |
| 2024-10-08 | 2024-10-04 | XFOR | X4 Pharmaceuticals, Inc | DiBiase Mary | COO | A - Grant | $0.00 | +230.6K | 519.8K | +80% | $0 | |
| 2024-10-08 | 2024-10-07 | XFOR | X4 Pharmaceuticals, Inc | DiBiase Mary | COO | S - Sale | $0.57 | -67.7K | 452.1K | -13% | -$38.6K | |
| 2024-09-11 | 2024-09-09 | XFOR | X4 Pharmaceuticals, Inc | DiBiase Mary | COO | S - Sale | $0.66 | -2,642 | 289.1K | -0.9% | -$1,744 | |
| 2024-03-11 | 2024-03-11 | XFOR | X4 Pharmaceuticals, Inc | DiBiase Mary | COO | S - Sale | $0.88 | -15.4K | 291.8K | -5% | -$13.6K | |
| 2024-02-12 | 2024-02-12 | XFOR | X4 Pharmaceuticals, Inc | DiBiase Mary | COO | S - Sale | $1.01 | -3,683 | 307.2K | -1% | -$3,720 | |
| 2023-11-03 | 2023-11-01 | XFOR | X4 Pharmaceuticals, Inc | DiBiase Mary | COO | S - Sale | $0.73 | -67.7K | 310.8K | -18% | -$49.4K | |
| 2023-11-02 | 2023-10-31 | XFOR | X4 Pharmaceuticals, Inc | DiBiase Mary | COO | A - Grant | $0.00 | +230.6K | 378.5K | +156% | $0 | |
| 2023-09-12 | 2023-09-08 | XFOR | X4 Pharmaceuticals, Inc | DiBiase Mary | COO | S - Sale | $1.25 | -2,642 | 147.9K | -2% | -$3,302 | |
| 2023-07-05 | 2023-06-30 | XFOR | X4 Pharmaceuticals, Inc | DiBiase Mary | COO | S - Sale | $1.89 | -464 | 150.5K | -0.3% | -$876.96 | |
| 2023-06-26 | 2023-06-23 | XFOR | X4 Pharmaceuticals, Inc | DiBiase Mary | COO | S - Sale | $1.93 | -857 | 151.0K | -0.6% | -$1,654 | |
| 2023-06-16 | 2023-06-15 | XFOR | X4 Pharmaceuticals, Inc | DiBiase Mary | COO | S - Sale | $2.23 | -857 | 151.9K | -0.6% | -$1,911 | |
| 2023-03-13 | 2023-03-10 | XFOR | X4 Pharmaceuticals, Inc | DiBiase Mary | COO | S - Sale | $0.84 | -18.2K | 152.7K | -11% | -$15.3K | |
| 2023-02-15 | 2023-02-13 | XFOR | X4 Pharmaceuticals, Inc | DiBiase Mary | COO | S - Sale | $0.93 | -4,348 | 170.9K | -2% | -$4,044 | |
| 2022-08-19 | 2022-08-17 | XFOR | X4 Pharmaceuticals, Inc | DiBiase Mary | COO | S - Sale | — | -1,713 | 177.9K | -1.0% | — | |
| 2022-07-01 | 2022-06-30 | XFOR | X4 Pharmaceuticals, Inc | DiBiase Mary | COO | S - Sale | — | -1,578 | 179.6K | -0.9% | — | |
| 2022-06-27 | 2022-06-24 | XFOR | X4 Pharmaceuticals, Inc | DiBiase Mary | COO | S - Sale | — | -856 | 181.2K | -0.5% | — | |
| 2022-06-17 | 2022-06-16 | XFOR | X4 Pharmaceuticals, Inc | DiBiase Mary | COO | S - Sale | — | -856 | 182.0K | -0.5% | — | |
| 2022-03-01 | 2022-03-01 | XFOR | X4 Pharmaceuticals, Inc | DiBiase Mary | COO | A - Grant | $0.00 | +105.0K | 182.9K | +135% | $0 | |
| 2022-02-14 | 2022-02-11 | XFOR | X4 Pharmaceuticals, Inc | DiBiase Mary | COO | S - Sale | — | -12.5K | 77.9K | -14% | — | |
| 2021-09-10 | 2021-09-08 | XFOR | X4 Pharmaceuticals, Inc | DiBiase Mary | COO | A - Grant | $0.00 | +27.0K | 90.4K | +43% | $0 |
Purchase Sale Sale after option exercise All abbreviations